Risk Evaluation of Abnormal Liver Function Associated with LMWH in 76 PTE Patients of Our Hospital
- Author:
Zi-Nan ZHAO
1
Author Information
- Publication Type:Journal Article
- Keywords: Abnormal liver function; Adverse drug reaction; Low molecular heparin; Pulmonary thromboembolism; Risk evaluation; Risk factor
- From: Chinese Pharmaceutical Journal 2017;52(16):1456-1459
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To explore the clinical regularities and risk factor of abnormal liver function associated with LMWH in pulmonary thromboembolism patients. METHODS: Clinical date of pulmonary thromboembolism patients in use of LMWH was collected and analyzed from January 2008 to December 2016. RESULTS: 97 cases were enrolled. Of them, there were 76 cases were assessed as probable or possible. Single factor analysis showed the the levels of Scr (P=0.000), ALT (P=0.000), AST (P=0.000), γ-GGT (P=0.000), ALP (P=0.023), co-infection (P=0.024) and Ccr (P=0.026) had statistically significant difference. Multivariate analysis indicated that co-infection (OR=1.982, P=0.022) and high level of Scr (OR=1.045, P=0.000) were the independent risk factors of abnormal liver function associated with LMWH in PTE. CONCLUSION: The incidence of abnormal liver function due to LMWH in PTE patients is high. With high level of Scr and/or co-infection patients are high-risk persons of abnormal liver function. It is necessary to dynamically evaluate the liver function during hospitalization. Symptomatic treatment can be significant if the liver function become abnormal.
